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Identiﬁcation of non-fermenting Gram-negative bacteria (NFGNB) from cystic ﬁbrosis (CF) patients is often limited. A collection of stored
NFGNB isolates (n=182) recovered from CF patients over a 15 year period was examined. The routinely reported identiﬁcation during this period
was compared with that obtained by MALDI-TOF MS. Isolates giving discrepant identiﬁcation at the genus level were further analyzed by 16S
rDNA sequencing. The MALDI-TOF MS system identiﬁed 94% of the isolates, including Burkholderia cepacia and Pandoraea spp. isolates,
the latter previously misidentiﬁed as other NFGNB by conventional microbiological methods. Lack of identiﬁcation by MALDI-TOF MS was as-
sociated with the absence of entries in the database.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Proteomic identiﬁcation; MALDI-TOF MS; Non-fermenting isolatesNon-fermenting Gram-negative bacteria (NFGNB) are environ-
mental organisms that can cause opportunistic severe infections,
especially in immunocompromised patients. In cystic fibrosis
(CF) patients, the main causes of morbidity and mortality are the
decline in pulmonary function secondary to pathogenic coloniza-
tion with NFGNB [1]. Nevertheless, different bacterial species in
CF-patients display distinct degrees of pathogenicity, thus requir-
ing different clinical management [2]. Correct identification of
these bacteria by conventional microbiology methods is often lim-
ited due to low biochemical reactivity [3]. Moreover, isolates from
patients with chronic pathogenic colonization often lose their char-
acteristic phenotypes or growth conditions [4]. In addition, bacteri-
al misidentification could be due to the fact that the species are not
in the database of the commercial systems used in clinical labora-
tories. In these cases, molecular tools such as 16S rDNA gene⁎ Corresponding author. Tel.: +34 913368330; fax: +34 913368809.
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doi:10.1016/j.jcf.2011.09.001sequencing provide reliable results, although it might have prob-
lems to assign at specie level [5].
Recently, several studies have reported the use of matrix-
assisted laser desorption ionization-time of flight mass spectrom-
etry (MALDI-TOF MS) for bacterial identification, including
NFGNB [6, 7]. This technique has been recently introduced in
clinical microbiology laboratories [8]. It is based on relative
molecular masses of proteins producing specific mass-spectral
fingerprints for different organisms. The reproducibility of the
MALDI-TOF MS is based on the measurement of high-
abundance proteins, including ribosomal proteins and the final
identification is not significantly influenced by variability in envi-
ronmental or growth conditions.
In this study we reassessed by MALDI-TOF MS historical
routine identification results obtained by conventional methods
of NFGNB recovered from sputum samples from 70 CF-patients
attended in our CF-Unit from 1994 to 2009 and obtained during
routine follow-up visits or during exacerbations. Pseudomonas
aeruginosa and Stenotrophomonas maltophilia isolates wereby Elsevier B.V. All rights reserved.
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routine conventional methods [9, 10].
A total of 182 isolates (66 Achromobacter spp., 54 Burkhol-
deria spp., 16 Acinetobacter spp., 7 non-aeruginosa Pseudomo-
nas, 8 Chryseobacterium spp., 7 Bordetella spp., 4 Ralstonia
spp., 4 Ochrobactrum anthropi, and 16 other NFGNB) sequen-
tially isolated during the study period and stored at −80 °C
were studied. Conventional routine identification at the species
level was performed at the time of isolation over the 15 year pe-
riod using various phenotypic tests including the PASCO
(Difco, Detroit, MI) or WIDER (Fco. Soria-Melguizo, Madrid,
Spain) systems. When this identification did not satisfy the cri-
teria for acceptance, then the API20NE (BioMérieux, Marcy-L´
Étoile, France) gallery was performed. The identification using
the MALDI-TOF MS was performed by the direct colony
method with a Microflex LT instrument using the FlexControl
3.0 and MALDI BioTyper 2.0 software (Bruker Daltonics
GmbH, Leipzig, Germany). Only scores above 1.7 were con-
sidered for identification and names of the best match of the da-
tabase were recorded. When MALDI-TOF MS and phenotypic
identifications agreed, no further methods were performed. Dis-
crepancies at genus level were resolved with a sequenced-based
molecular technique (PCR of 16S rDNA) that was considered
as the “gold standard” identification method [5]. Moreover,
this molecular technique was also applied when MALDI-TOF
MS yield no identification. No further molecular characteriza-
tion techniques (e.g. recA or gyrB-based sequencing) were
used to improve isolate identification at species level.
Conventional and MALDI-TOF MS identification results
are shown in Table 1. Performance of the MALDI-TOF MS
system was significantly better for identification than con-
ventional routine biochemical phenotypic tests. Overall, one
hundred seventy one out of 182 isolates (94%) were identi-
fied by mass spectrometry. Eighty percent (145/182) of stud-
ied isolates displayed identical identification at genus level
when compared phenotypic and MALDI-TOF MS methods
but decreased to 68% at species level when compared with
routine identification obtained with conventional methods
(see below).
Among previously identified Achromobacter xylosoxidans
isolates by conventional methods (n=66), only fifty-six (85%)
confirmed this identification by MALDI-TOF MS at specie
level whereas the other isolates were identified as different
Achromobacter species, and also to some emerging pathogens
in CF, including Pandoraea spp. This result is of clinical inter-
est as A. xylosoxidans within Achromobacter genera has been
demonstrated to cause persistent respiratory tract infection and
inflammation in CF-patients similar to that of P. aeruginosa
[11]. Similarly, MALDI-TOF MS is able to differentiate differ-
ent species within the Burkholderia cepacia complex [6, 7]. In
our study, we speciated B. cepacia isolates by MALDI-TOF
MS as Burkholderia cenocepacia (n=29), Burkholderia vietna-
miensis (n=8), Burkholderia cepacia (n=2) and Burkholderia
multivorans (n=2). Speciation within this complex is specifi-
cally recommended not only for the clinical management of
these patients but also for infection control measures [12, 13].
Conversely, seven isolates in our study previously identified asB. cepacia were speciated by MALDI-TOF MS as Burkholderia
gladioli, showing that conventional identification was not reliable
for this specie (Table 1). MALDI-TOF MS spectra from our B.
gladioli isolates accurately matched with that obtained with a
quality control B. gladioli strain (data not shown).
In addition, six isolates were confirmed as non belonging
to the B. cepacia complex. These included three isolates of
Pandoraea spp. which had never been previously identified
by conventional methods in our laboratory. This organism
has been recovered from the respiratory tracts of CF-patients
and differentiation from B. cepacia complex organisms may
be problematic [14].
In the case of other organisms rarely isolated from CF-patients
included in our study, we demonstrated that conventional identi-
fication methods were also misleading and unreliable due to the
absence of different species in the manufacturers' databases.
This was the case of different species within the Acinetobacter
[15] and Chryseobacterium [16] genus. Also, MALDI-TOF MS
improved the identification of five strains previously character-
ized as Pseudomonas fluorescens group. On the contrary, an ac-
curate identification of Ralstonia pickettii (n=4) by automated
phenotypic identification methods was obtained.
Discrepancies (n=19) of routine phenotypic and MALDI-TOF
MS identifications at genus level were resolved by 16S rDNA
gene sequencing in favor of the last one. Lack of identification
(6% of isolates, n=11) with MALDI-TOF MS was resolved by
16S rDNA gene sequencing as Ralstonia spp. (n=5), Bordetella
petrii (n=3),Chryseobacterium spp. (n=2) and Sphingobacterium
spirituvorum (n=1), all of them occasionally isolated from CF-
patients [16] (Table 1). “No identification” results by MALDI-
TOF MS were clearly associated with an absence of sufficient
spectra from suitable reference strains in the database.
Previous studies described the performance of MALDI-TOF
MS for bacterial identification [17]. Our current manuscript
shows how this system, using a commercial database, improves
routine identification of CF isolates. We showed that MALDI-
TOF MS is a reliable and versatile tool for identification of
NFGNB bacteria recovered from CF-patients that usually have
limited biochemical reactivity leading to misidentification when
using classical phenotypic approaches. Despite its accuracy,
MALDI-TOF MS database needs to be updated and enlarged
with a wider range of microbial species including infrequent or
rare organisms recovered from CF-patients. The implementation
of MALDI-TOF MS system in the routine identification process-
es of CF isolates will not only reduce time-to-report but also pro-
vide value information for antimicrobial treatment. Moreover,
correct identification of these organisms has been highlighted in
the infection control guidelines of CF-patients as a first step in
their clinical management [18, 19].Acknowledgments
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Table 1
Comparative identification of non-fermenting Gram-negative bacilli by routine methods and MALDI TOF MS.
Phenotypic identiﬁcation (no.) MALDI-TOF MS identiﬁcation (no.) Resolution of discrepant results using 16S rDNA gene sequencing (no.)
Achromobacter xylosoxidans (66) Achromobacter xylosoxidans (56)
Achromobacter ruhlandii (1)
Achromobacter insolitus (1)
Achromobacter spanius (2)
Pandoraea spp. (3) Pandoraea spp. (3)
Acinetobacter spp. (1) Acinetobacter spp. (1)
No identification (2) Ralstonia spp. (2)
Burkholderia cepacia complex (54) Burkholderia cenocepacia (29)
Burkholderia vietnamiensis (8)
Burkholderia cepacia (2)
Burkholderia multivorans (2)
Burkholderia gladioli (7)
Pandoraea spp. (3) Pandoraea spp.(3)
Achromobacter xylosoxidans (2) Achromobacter xylosoxidans (2)
Pseudomonas huttiensis (1) Pseudomonas huttiensis (1)
Acinetobacter lwoffii complex (8) Acinetobacter ursingii (3)
Acinetobacter johnsonii (1)
Acinetobacter spp. (3)
Agrobacterium tumefaciens (1) Agrobacterium tumefaciens (1)
Acinetobacter baumanii (8) Acinetobacter baumannii (1)
Acinetobacter spp. (3)
Ochrobactrum anthropi (1) Ochrobactrum spp. (1)
Pseudomonas spp. (1) Pseudomonas spp. (1)
Achromobacter spp. (1) Achromobacter spp. (1)
No identification (1) Bordetella petrii (1)
Pseudomonas fluorescens/putida (6) Pseudomonas libanensis (2)
Pseudomonas gessardi (1)
Pseudomonas tolaasii (1)
Pseudomonas koreensis (1)
Achromobacter xylosoxidans (1) Achromobacter xylosoxidans (1)
Pseudomonas stutzeri (1) Pseudomonas stutzeri (1)
Chryseobacterium indologenes (6) Chryseobacterium indologenes (3)
Chryseobacterium joostei (3)
Chryseobacterium meningosepticum (2) Brevibacillus reuszeri (1) Brevibacillus reuszeri (1)
No identification (1) Chryseobacterium gleum (1)
Bordetella bronchiseptica (7) Bordetella bronchiseptica (4)
No identification (3) Bordetella petrii (2), Ralstonia spp. (1)
Ralstonia pickettii (4) Ralstonia pickettii (4)
Ochrobactrum anthropi (4) Ochrobactrum anthropi (2)
Ochrobactrum grignonense (1)
No identification (1) Chryseobacterium spp. (1)
Agrobacterium tumefaciens (1) Agrobacterium tumefaciens (1)
Alacaligenes spp. (1) Achromobacter insolitus (1)
Chromobacterium violaceum (1) Pseudomonas fragi (1) Pseudomonas spp. (1)
Delftia acidovorans (1) Delftia acidovorans (1)
Empedobacter brevis (1) Acinetobacter junii (1) Acinetobacter johnsonii (1)
NFGNB (11) Arthrobacter castelli (1) Arthrobacter spp. (1)
Brevundimonas vesicularis (1) Brevundimonas diminuta (1)
Bordetella bronchiseptica (2) Bordetella spp. (2)
Chryseobacterium indologenes (1) Chryseobacterium spp. (1)
Oligella urethralis (1) Oligella spp. (1)
Pandoraea spp. (1) Pandoraea spp. (1)
Sphingobacterium spiritivorum (1) Sphingobacterium spiritivorum (1)
No identification (3) Ralstonia spp.(2), Chryseobacterium spp.(1)
NFGNB: non fermenting Gram-negative bacilli.
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